Ezra Cohen

Trials

Studies that name Ezra Cohen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:38 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT05153304 · Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers

  University of California, San Diego · withdrawn · Cancer of Gastrointestinal Tract · principal investigator
• Ph1
  NCT03991741 · Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

  Gregory Daniels · terminated · Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer · principal investigator
• Ph2
  NCT03795610 · IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma

  Assuntina G. Sacco, MD · completed · Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma · principal investigator
• Ph2
  NCT02644122 · SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

  Ezra Cohen · terminated · Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma · principal investigator
• N/A
  NCT02543476 · SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

  AstraZeneca · completed · Squamous Cell Carcinoma of the Head and Neck · principal investigator
• Ph1/Ph2
  NCT02521870 · A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  Dynavax Technologies Corporation · terminated · Metastatic Melanoma, Head Neck Cancer · principal investigator
• Ph2
  NCT01836029 · Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

  Celgene · completed · Carcinoma, Squamous Cell of Head and Neck · study chair
• Ph2
  NCT01185158 · A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

  University of Chicago · completed · Head and Neck Cancer · principal investigator
• Ph2
  NCT01172470 · Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients

  University of Chicago · completed · Head and Neck Cancer · principal investigator
• Ph1
  NCT00708591 · Study of Rapamycin Plus Ketoconazole in Advanced Cancers

  University of Chicago · completed · Advanced Cancer · principal investigator
• Ph1
  NCT00667485 · Rapamycin Plus Bevacizumab in Advanced Cancers

  University of Chicago · completed · Advanced Cancer, Metastatic Cancer · principal investigator
• N/A
  NCT00619242 · The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer

  University of Chicago · terminated · Esophageal Cancer · principal investigator
• Early Ph1
  NCT00583063 · Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers

  University of Chicago · completed · Solid Tumors · principal investigator
• Ph1
  NCT00449280 · Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies

  University of Chicago · completed · Advanced Solid Tumor · principal investigator
• Ph2
  NCT00387335 · Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

  National Cancer Institute (NCI) · completed · Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx · principal investigator
• Ph2
  NCT00098631 · Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

  National Cancer Institute (NCI) · completed · Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 06:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Protocol Review and Monitoring Committee
  P30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2019 to 2023 · $183,050 awarded in 2023
  Same name and institution; not confirmed by an ID
• Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC
  R01CA247551 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2020 to 2022 · $489,974 awarded in 2022
  Same name and institution; not confirmed by an ID
• A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States
  U01CA217885 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2017 to 2021 · $942,132 awarded in 2021
  Same name and institution; not confirmed by an ID
• Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells
  R01CA134633 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2017 to 2021 · $459,865 awarded in 2021
  Same name and institution; not confirmed by an ID
• Therapeutic Targeting of Macrophage PI3Kgamma in HNSCC
  R01CA226909 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2018 to 2021 · $472,763 awarded in 2021
  Same name and institution; not confirmed by an ID
• Basic Medical Research Training in Oncology
  T32CA009566 · NCI · UNIVERSITY OF CHICAGO · fiscal years 2012 to 2014 · $409,084 awarded in 2014
  Same name and institution; not confirmed by an ID
• Maximizing Efficacy of EGFR Inhibitors by Defining Resistance Mechanisms
  R21DE022454 · NIDCR · UNIVERSITY OF CHICAGO · fiscal years 2012 to 2013 · $189,600 awarded in 2013
  Same name and institution; not confirmed by an ID
• Functional Infrared Imaging Predicts Radiation Mucositis
  R21CA125000 · NCI · UNIVERSITY OF CHICAGO · fiscal years 2007 to 2008 · $171,287 awarded in 2008
  Same name and institution; not confirmed by an ID
• Rapamycin as an Antineoplastic Agent
  R21CA112951 · NCI · UNIVERSITY OF CHICAGO · fiscal years 2005 to 2006 · $295,878 awarded in 2006
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Clinical and Experimental Therapeutics
  P30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI Wendy Stock · fiscal years 2010 to 2026
  Named on NCT00387335